Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical firm Kadmon has dosed the first patient in a Phase II clinical trial (Study 206) of KD025 to treat moderate to severe psoriasis vulgaris who failed first-line therapy.
Subscribe to our email newsletter
The Phase II trial is designed to evaluate the safety, efficacy and tolerability of KD025, the company’s orally bioavailable, potent and highly selective inhibitor of Rho-associated coiled-coiled kinase 2 (ROCK2), in these patients.
In the open-label, dose-finding trial, KD025 will examined when administered at doses of 200mg twice daily and 400mg once daily for three months in 24 patients at six sites in the US.
In a Phase IIa single-arm safety trial, KD025 showed encouraging pharmacodynamic activity at a lower dose of 200mg once daily.
Kadmon executive vice-president and chief medical officer Dr John Ryan said: "Selective ROCK2 inhibition by KD025 has demonstrated activity in preclinical models of autoimmune and fibrotic diseases. We have also demonstrated clinical activity of KD025 in a Phase IIa trial of psoriasis.
"We believe this Phase II study will provide further insight into the unique activity of KD025 and its potential in treating these diseases."
The company said that administration of KD025 200mg once daily was generally well tolerated, with all patients showing the previously showed positive changes in inflammatory markers, including a specific decrease in the secretion of IL-17, a pro-inflammatory cytokine.
Furthermore, three of the eight patients showed a decrease in Psoriasis Area and Severity Index (PASI) scores of up to 66% after only one month of treatment.